M
Maxwealth Fund Management Co., Ltd
+ HoldingZLAB
+19.28%
3M Return
$26.080
-0.720 (-2.76%)At close
Loading chart…
- High
- 26.450
- Open
- 26.450
- VWAP
- 26.13
- Vol
- 650.04K
- Mkt Cap
- 1.73B
- Low
- 25.868
- Amount
- 16.99M
- EV/EBITDA, TTM
- -6.79
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
AI analysis of Zai Lab Ltd (ZLAB)
buyZai Lab Ltd appears to be a good buy right now due to its recent positive developments and strong analyst support. The current price is $26.08, and the RSI is at 57.16, indicating a healthy momentum. Additionally, the company has received FDA Orphan Drug status for its antibody-drug conjugate, which could significantly enhance its market position. However, the main risk is the increasing insider selling, which has risen by 126% over the last month, indicating potential concerns about the company's future performance.
Analyst Ratings (3)
+83.78% upside
Buy
2 Buy
1 Hold
0 Sell
Current: 26.08
Low
25.70
Average
47.93
High
74.00
JPMorgan
Overweight
$36
2026-08-27
JPMorgan
2026-08-27
Price Target
$36
Overweight
Citi
Buy
$45
2026-08-07
Citi
2026-08-07
Price Target
$45
Buy
Citi
Buy
$44
2026-05-08
Citi
2026-05-08
Price Target
$44
Buy
JPMorgan
Overweight
$32
2026-03-18
JPMorgan
2026-03-18
Price Target
$32
Overweight
Cantor Fitzgerald
Overweight
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
Price Target
$37
Overweight
Valuation Metrics
The current forward P/E ratio for Zai Lab Ltd (ZLAB) is 0.00, compared to its 5-year average forward P/E of -16.46.
Whales holding ZLAB
Events Timeline
News
5.008-27CNBCZ.ai Launches Homegrown AI Model, Shares Surge 8%
8.508-17NewsfilterZai Lab and argenx Announce Positive ALKIVIA Study Results
9.508-06seekingalphaZai Lab Q2 Earnings Beat Expectations with $106.3M Revenue
- 9.508-06Newsfilter
Zai Lab Advances Global Oncology and Immunology Programs with Key Milestones
9.008-03seekingalphaZai Lab's Antibody-Drug Conjugate Receives FDA Orphan Drug Status
ZLAB FAQ — answered by Alphio AI
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd appears to be a good buy right now due to its recent positive developments and strong analyst support. The current price is $26.08, and the RSI is at 57.16, indicating a healthy momentum. Additionally, the company has received FDA Orphan Drug status for its antibody-drug conjugate, which could significantly enhance its market position. However, the main risk is the increasing insider selling, which has risen by 126% over the last month, indicating potential concerns about the company's future performance.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.